VivoSeq
Metabolic & Endocrine

Partial Lipodystrophy

4

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Partial Lipodystrophy is an early-stage landscape with 4 programs across 4 companies. The most active players are Rhythm Pharmaceuticals, Eli Lilly, Chiesi Farmaceutici S.p.A.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Rhythm Pharmaceuticals logo

Rhythm Pharmaceuticals

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

1 program

Phase 3A

Amryt Pharma

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

4programs
Small molecule250%
Peptide250%

Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting3 · 50%
Completed3 · 50%

Clinical Trials

Trial Activity

6 trials

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Recruiting·AAmryt Pharma·Phase 3·NCT06679270·24 enrolled
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
Recruiting·UUniversity of Michigan·Phase 2·NCT07091734·32 enrolled
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Recruiting·AAmryt Pharma·Phase 4·NCT06484868·12 enrolled
Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT02639286·5 enrolled
Setmelanotide in a Single Patient With Partial Lipodystrophy
Completed·Rhythm Pharmaceuticals logoRhythm Pharmaceuticals·Phase 2·NCT03262610·1 enrolled
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
Completed·UUniversity of Michigan·Phase 2·NCT02654977·11 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)